2023 World Conference on Lung Cancer (Posters)-EP07.01. Nomogram for Predictingprognosis andAdjuvant Chemotherapy BenefitsinEarly-stageInvasive Mucinous Lung Adenocarcinoma

EP07.01. Nomogram for Predictingprognosis andAdjuvant Chemotherapy BenefitsinEarly-stageInvasive Mucinous Lung Adenocarcinoma - PDF(Slides)

Back to course

Pdf Summary

A study has developed a nomogram model for predicting prognosis and identifying patients who would benefit from adjuvant chemotherapy (ACT) for stage I-IIA invasive mucinous lung adenocarcinoma (IMA). The nomogram was found to have better performance than the 8th TNM stage in predicting recurrence, and it could identify potential candidates for ACT. Previous models did not effectively predict recurrence-free survival and identify patients who could benefit from ACT in early-stage I/II IMA. The NCCN guideline recommends ACT for high-risk patients in stage IB/IIA, but some studies have shown that ACT can improve survival even in stage IA NSCLC. The nomogram was developed by integrating independent risk factors identified through univariate and multivariate Cox regression analysis for recurrence-free survival. These risk factors included visceral pleural invasion, lymph-vascular invasion, tumor size, smoking history, and lobulation. The nomogram showed higher performance in terms of AUC and C-index compared to the 8th TNM stage in the validation cohort. Decision curve analysis also demonstrated additional benefits for predicting recurrence-free survival using the nomogram. In the training and validation cohorts, there was a significant difference in recurrence-free survival between the high- and low-risk groups. Patients who received ACT had superior 5-year recurrence-free survival compared to non-ACT patients in the high-risk group, while no difference in survival was observed in the low-risk group. The study concludes that the nomogram can effectively predict recurrence and identify patients who would benefit from ACT in stage I-IIA IMA.

Asset Subtitle

Hua He

Meta Tag

Speaker Hua He

Topic Early-Stage NSCLC: Best Practice

Keywords

nomogram model

adjuvant chemotherapy

invasive mucinous lung adenocarcinoma

recurrence

high-risk patients

stage IA NSCLC

risk factors

lymph-vascular invasion

tumor size

recurrence-free survival